Moleculin Biotech
MBRX
25 hedge funds and large institutions have $5.61M invested in Moleculin Biotech in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
19% more funds holding
Funds holding: 21 → 25 (+4)
0% more ownership
Funds ownership: 0.03% → 0.03% (+0%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
35% less capital invested
Capital invested by funds: $8.57M → $5.61M (-$2.96M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$110K |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$102K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$82.5K |
| 4 |
Renaissance Technologies
New York
|
+$78.9K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$52.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Truist Financial
Charlotte,
North Carolina
|
-$88K |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$43K |
| 3 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$17.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4K |
| 5 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
-$3.55K |
MBRX Hedge Fund Activity: Q4 2021 in Review
25 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2021, worth a combined $5.61M — down 35% from $8.57M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new MBRX positions and 4 closed out — a net gain of 4 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $110K. The largest seller was Truist Financial, exiting entirely with an estimated $88K sold.
- 25 institutional investors held Moleculin Biotech (MBRX) as of Q4 2021, up from 21 in Q3 2021.
- Funds reported $5.61M of Moleculin Biotech stock for Q4 2021, down 35% quarter-over-quarter.
- 8 funds opened new Moleculin Biotech positions in Q4 2021 and 4 closed out, a net change of +4 holders.
- The largest Moleculin Biotech buyer in Q4 2021 was Virtu Financial, an estimated $110K added.
- The largest Moleculin Biotech seller in Q4 2021 was Truist Financial, an estimated $88K sold.
Based on aggregated 13F filings for Q4 2021.